Lineage Cell's Dry Age-Related Macular Degeneration Cell Therapy Associated With Stable Or Improved Vision

Lineage Cell Therapeutics Inc LCTX has updated interim results from its ongoing Phase 1/2a study of its lead product candidate, OpRegen, for dry age-related macular degeneration (AMD) with geographic atrophy (GA).
OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells administered to the subretinal space.
Data were presented at the Association for Research in Vision and Ophthalmology Annual Meeting.
Additional data presented include 24 patients enrolled in the study, including all 12 patients treated in Cohort 4, which have better baseline vision and smaller GA areas than earlier cohorts.
Improvements in best-corrected visual acuity (BCVA) for Cohort 4 patients reached up to +19 letters.
In contrast, 10/12 of the patients' untreated eyes were below pre-treatment baseline values simultaneously.
Among the newly reported data, three of the more recently treated Cohort 4 patients exhibited marked improvements in BCVA, ranging from +7 to +16 letters.
Two additional Cohort 4 patients experienced a gain of 2 letters from their baseline values, while one patient measured seven letters below the baseline.
Overall, OpRegen was well tolerated with no unexpected adverse events or serious adverse events.
Also, evidence of durable engraftment of OpRegen RPE cells has extended to more than five years in the earliest treated patients, supporting the potential for OpRegen to be a one-time treatment.
Price Action: LCTX shares are down 0.4% at $2.74 on the last check Monday.

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga